Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sapanisertib in NFE2L2/KEAP1 Mutated NSCLC
NCT02417701Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2016
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sapanisertib in non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Started Oct 2016; status: completed.
02
Drugs
sapanisertib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02417701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02417701.